Literature DB >> 9002966

Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes.

A Venditti1, G Del Poeta, F Buccisano, A Tamburini, M C Cox, R Stasi, A Bruno, G Aronica, L Maffei, G Suppo, M D Simone, L Forte, V Cordero, M Postorino, V Tufilli, G Isacchi, M Masi, G Papa, S Amadori.   

Abstract

We compared the immunophenotypic and karyotypic features of 25 cases of minimally differentiated acute myeloid leukemia (AML-M0) with those of 247 cases comprising all AML French-American-British (FAB) classification. Myeloperoxidase (MPO) was detectable with a specific monoclonal antibody in all cases of AML-M0, whereas CD13 and CD33 were both negative in 4 of the 25 cases. Thus, anti-MPO reliably detects minimal myeloid differentiation in AML-M0. CD34 and terminal deoxynucleotidyl transferase (TdT) were more frequently expressed in AML-M0 (96% and 68% of the cases, respectively) than in the other FAB subsets (P < .001 for both). By contrast, GP-170 and CD7 were less frequently expressed in AML-M0 than in FAB classes such as M1, M4, and M5 (P = .02 and .003, respectively). A total of 80% of AML-M0 cases carried lymphoid markers (including TdT), and 48% showed a coordinate positivity for two or more of them. CD2, CD5, CD10, and CD19 were expressed in a similar fashion among the different FAB groups, whereas CD4 expression was significantly more frequent in AML-M0, AML-M4, and AML-M5 (P = .014). AML-M0 was characterized by a more frequent occurrence of complex karyotypes. In addition, approximately 20% of cases had TdT positivity, complex karyotypes, and anomalies of chromosome 5 and/or 7, a pattern not observed in the other FAB subsets. Finally, 80% of anomalies of chromosome 5 and/or 7 in AML-M0 were comprised within complex karyotypes, whereas only 13% of the remaining FAB cases carried this feature. In summary, AML-M0 frequently expresses immunophenotypic and karyotypic aspects that are likely to identify a "stem cell" pattern.

Entities:  

Mesh:

Year:  1997        PMID: 9002966

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.

Authors:  Deborah DeRyckere; Alisa B Lee-Sherick; Madeline G Huey; Amanda A Hill; Jeffrey W Tyner; Kristen M Jacobsen; Lauren S Page; Gregory G Kirkpatrick; Fatma Eryildiz; Stephanie A Montgomery; Weihe Zhang; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Douglas K Graham
Journal:  Clin Cancer Res       Date:  2016-09-20       Impact factor: 12.531

2.  TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.

Authors:  Keyur P Patel; Faisal A Khokhar; Tariq Muzzafar; M James You; Carlos E Bueso-Ramos; Farhad Ravandi; Sherrie Pierce; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2012-08-31       Impact factor: 7.842

3.  Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961.

Authors:  Draga Barbaric; Todd A Alonzo; Robert B Gerbing; Soheil Meshinchi; Nyla A Heerema; Dorothy R Barnard; Beverly J Lange; William G Woods; Robert J Arceci; Franklin O Smith
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

4.  Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Authors:  Ritsuro Suzuki; Makoto Murata; Masahiro Kami; Shigeki Ohtake; Norio Asou; Yoshihisa Kodera; Masao Tomonaga; Yasufumi Masaki; Shuya Kusumoto; Jin Takeuchi; Shin Matsuda; Hisamaru Hirai; m Seiichi Yorimitsu; Nobuyuki Hamajima; Masao Seto; Masanori Shimoyama; Ryuzo Ohno; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.